PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
|Articles|August 21, 2012
Sign Of Change: Doctors Offering Price Guarantee To Insurers
Advertisement
In what could be a surprising and growing trend, one of the Midwest’s largest providers of medical care is bringing a price guarantee to a new concept being pushed by the Obama administration that rewards doctors and hospitals for working together to improve quality.
Milwaukee-based Aurora Health Care has formed an Accountable Care Organization (ACO) that is working with Aetna Inc. (AET) and Wellpoint (WLP) subsidiary Anthem Blue Cross and Blue Shield in Wisconsin that are packaging commercial health insurance products using Aurora doctors and hospitals that offer small and mid-sized businesses a “price guarantee.”
Read the full story:
Source: Forbes
Advertisement
Related to this article
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
5